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Background. Androgen deprivation therapy (ADT) in nonmetastatic prostate cancer is unclear. Recent data suggests possible
increase in the cardiovascular risks receiving ADT.The aim of the study was to investigate the cardiovascular outcomes in a cohort
of Chinese nonmetastatic prostate cancer patients with no previously documented cardiovascular disease.Methods and Results. 745
patients with no previously documented cardiovascular disease and/or diabetes mellitus diagnosed to have nonmetastatic prostate
cancer were recruited. Of these, 517 patients received ADT and the remaining 228 did not. After a mean follow-up of 5.3 years, 60
patients developed primary composite endpoint including (1) coronary artery disease, (2) congestive heart failure, and (3) ischemic
stroke. Higher proportion of patients on ADT (51 patients, 9.9%) developed composite endpoint compared with those not on
ADT (9 patients, 3.9%) with hazard ratio (HR) of 2.06 (95% confidence interval (CI): 1.03–3.24, 𝑃 = 0.04). Furthermore, Cox
regression analysis revealed that only the use of ADT (HR: 2.1, 95% CI: 1.03–4.25, 𝑃 = 0.04) and hypertension (HR: 2.0, 95%
CI: 1.21–3.33, 𝑃 < 0.01) were independent predictors for primary composite endpoint. Conclusion. ADT in Chinese patients with
nonmetastatic prostate cancer with no previously documented cardiovascular disease was associated with subsequent development
of cardiovascular events.
1. Introduction
Carcinoma of prostate is the most common malignancy in
men and the incidence has been increasing during the past
two decades [1–3]. Androgen deprivation therapy (ADT)
in form of bilateral orchiectomy and/or medical castration
has been the mainstay systemic treatment in patients with
metastatic disease because of the androgen dependence of
the disease [1]. On the other hand, the role of ADT in
localized disease remains to be defined, asmany patients with
localized disease often have a favorable prognosis and may
live up to a near-normal lifespan. Thus, treatments aiming
to further improve the long-term outcomes in these patients
should outweigh any potential treatment-associated adverse
effects. In recent years, the metabolic effects as well as the
cardiovascular consequences of ADT had been increasingly
recognized. However, clinical data concerning ADT-related
adverse metabolic and cardiovascular effects remain conflict-
ing [4]. There have been studies demonstrating that patients
receiving ADT may have a higher incidence of diabetes mel-
litus [5–7], coronary artery disease [5, 6], stroke [6, 7], and/or
even cardiovascular death [8–10], but other studies failed to
show such associations [7, 11, 12]. This may be due to the fact
that, in these studies, the presence of preexisting metabolic
condition and other cardiovascular diseases had not been
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adequately characterized and/or controlled. Furthermore,
previous studies often include a rather heterogeneous pop-
ulation from patients with distant metastasis, in whom ADT
has convincingly been demonstrated to have survival benefits
[13], to those with early disease in whom treatments may not
be necessary. The aim of the present study is to investigate
the cardiovascular outcomes in a cohort of Chinese patients
with nonmetastatic cancer of prostate with no previously
documented diabetes mellitus and cardiovascular disease.
2. Methods
2.1. Patients. Between January 1998 and September 2011, 1,116
Chinese patients with a diagnosis of carcinoma of prostate at
Queen Mary Hospital, Hong Kong, were identified through
the computer-based clinical management system. Patients
were excluded if they had distant metastasis at the time of
diagnosis, previously documented diabetes mellitus, coro-
nary artery disease, congestive heart failure, ischemic stroke,
chronic renal failure, and/or atrial fibrillation. As a result, the
final analysis included 745 patients with nonmetastatic carci-
noma of prostate, and they were then categorized according
to the use of androgen deprivation therapy.
2.2. Study Design. This was a single-centered observational
study. Data pertaining to the index carcinoma of prostate,
demographics, cardiovascular risk factors, and medications
were entered into the ClinicalManagement SystemDatabase.
The primary endpoint was a composite of new occurrence
of coronary artery disease, congestive heart failure, and
ischemic stroke during the follow-up period. All the patients
were followed up in our outpatient clinic. Deaths within
the follow-up period after the recruitment were retrieved
from the medical records and discharge summaries from
our hospital as well as other institutions. Patients who failed
to attend the clinic were contacted by phone. In addition,
survival data were obtained from the Births and Deaths
General Register Office.
2.3. Statistical Analysis. Continuous variables are expressed
as mean ± standard error of mean. Statistical comparisons
were performed using Student’s 𝑡-test or Fisher’s exact test,
as appropriate. Kaplan-Meier survival analysis with the log-
rank test was used to calculate cumulative incidences of coro-
nary artery disease, congestive heart failure, and ischemic
stroke. Multivariate analyses were performed with an enter
regression model in which each variable with a 𝑃 value ≤0.1
(based on the univariate analysis) was entered into themodel.
Calculations were performed using SPSS software (version
12.0). A 𝑃 value <0.05 was considered statistically significant.
3. Results
A total of 745 patients (mean age: 72.2 ± 0.3 years) with
nonmetastatic carcinoma of prostate were recruited, of whom
517 patients (69.3%) received ADT and the remaining 228
patients (30.7%) did not. Amongst patients receiving ADT,
nearly half of them (48.7%) received medical ADT, 24.7%
received surgical ADT, and 26.6% received both medical
and surgical ADT. Table 1 summarizes the baseline clinical
characteristics of the study population. Patients onADTwere
older (73.5 ± 0.4 years versus 69.2 ± 0.6 years, 𝑃 < 0.01)
and had a higher prevalence of being a smoker (41.4% versus
30.7%, 𝑃 < 0.01), but a lower prevalence of hypercholes-
terolemia (8.1% versus 16.2%, 𝑃 < 0.01) compared with
patients not on ADT (Table 1). Concerning the tumor status,
patients on ADT had a higher serum level of prostate specific
antigen (430 ± 59 ng/mL versus 93 ± 44 ng/mL, 𝑃 < 0.01),
had a higher Gleason score, and are less likely to receive local
treatment such as radical prostatectomy and/or radiotherapy
(56.3% versus85.5%, 𝑃 < 0.01) (Table 1).
After a mean follow-up of 5.3 ± 0.1 years, 60 patients
(8.1%) developed the primary composite endpoint (coronary
artery disease, congestive heart failure, and ischemic stroke)
with an annual incidence of 16.0 events per 1,000 patient-
years. Of these, 51 patients were on ADT (9.9%; annual
incidence: 18.6 per 1,000 patient-years) and the remaining
9 patients were not (3.9%; annual incidence: 8.9 per 1,000
patient-years). Figure 1 depicts the Kaplan-Meier composite
endpoint-free survival in patients on ADT and not on
ADT. Patients on ADT had a significantly higher risk in
developing the primary composite endpoint during follow-
up period than those not on ADT (hazard ratio (HR) 2.06;
95% confidence interval (CI): 1.03–3.24, 𝑃 = 0.04). In
order to identify independent risk factors predicting the
occurrence of primary composite endpoint, patients were
categorized into (1) those with primary endpoint (𝑛 = 60)
and (2) those without primary endpoint (𝑛 = 685). Table 2
summarizes the clinical characteristics of patients with and
without primary composite endpoint. Patients with primary
composite endpoint had higher proportions of hypertension
(53.5% versus 35.6%, 𝑃 < 0.01) and receiving ADT (85.0%
versus 68.0%, 𝑃 < 0.01). However, there were no statistically
significant differences in age and other cardiovascular risk
factors, as well as tumor status (serum PSA level and Gleason
score). Cox regression analysis revealed that only ADT (HR:
2.1, 95% CI: 1.03–4.25, 𝑃 = 0.04) and hypertension (HR: 2.0,
95% CI: 1.21–3.33, 𝑃 < 0.01) were independent predictors for
primary composite endpoints.
In the analysis of the subcomponents of the primary end-
point, there were 30 newly diagnosed with coronary artery
disease (7.7 per 1,000 patient-years), 14 with congestive heart
failure (3.5 per 1,000 patient-years), and 21 with ischemic
strokes (5.4 per 1,000 patient-years). For newly diagnosed
coronary artery disease, 27 out of 30 occurred in patients on
ADT (5.2%, 9.9 per 1,000 patient-years) and 3 in those not
on ADT (1.3%, 2.6 per 1,000 patient-year). For patients on
ADT, the proportion of patients developed coronary artery
disease during follow-up period was significantly higher than
that not on ADT with hazard ratio of 3.70 (95% confidence
interval (CI): 1.15–5.57, 𝑃 = 0.02). Likewise, patients on ADT
weremore likely to develop CHF; all 14 newly diagnosed with
CHF in fact occurred in patients on ADT (2.7% (4.9 per 1,000
patient-year) versus0% (0 per 1,000 patient-year), 𝑃 = 0.04).
However, there was no statistically significant difference in
the ischemic stroke risk between patients on ADT (2.9%, 5.2
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Table 1: Baseline characteristics of patients with and without androgen deprivation therapy.
All (𝑁 = 745) ADT (𝑁 = 517) No ADT (𝑁 = 228) 𝑃-value
Age, years 72.2 ± 0.3 73.5 ± 0.4 69.2 ± 0.6 <0.01∗
Hypertension, 𝑛 (%) 276 (37.0) 189 (36.6) 87 (38.2) 0.68
Hypercholesterolemia, 𝑛 (%) 79 (10.6) 42 (8.1) 37 (16.2) <0.01∗
Cigarette smoker, 𝑛 (%) 284 (38.1) 214 (41.4) 70 (30.7) <0.01∗
Lung disease, 𝑛 (%) 26 (3.5) 21 (4.1) 5 (2.2) 0.28
Carcinoma of prostate
PSA at diagnosis (ng/mL) 326 ± 43 430 ± 59 93 ± 44 <0.01∗
Gleason score <0.01∗
2–5, 𝑛 (%) 40 (5.4) 25 (4.8) 15 (6.6)
6–8, 𝑛 (%) 481 (64.6) 291 (56.3) 190 (83.3)
9-10, 𝑛 (%) 141 (18.9) 131 (25.3) 10 (4.4)
Not specified, 𝑛 (%) 83 (11.1) 70 (13.4) 13 (5.7)
Treatment
Local treatment, 𝑛 (%) 486 (65.2) 291 (56.3) 195 (85.5) <0.01∗
Surgical ADT only, 𝑛 (%) 128 (17.2) 128 (24.7) —
Medical ADT only, 𝑛 (%) 252 (33.8) 252 (48.7) —
Medical and Surgical ADT, 𝑛 (%) 137 (18.4) 137 (26.6) —
∗
𝑃 < 0.05 (comparison between patients with and without ADT).
ADT: androgen deprivation therapy; PSA: prostate specific antigen.
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Figure 1: Kaplan-Meier curve of primary composite endpoint
(coronary artery disease, congestive heart failure, and ischemic
stroke) in patients on ADT and those not on ADT.
per 1,000 patient-year) and those not on ADT (2.6%, 5.9 per
1,000 patient-year) (HR: 0.94, 95% CI: 0.35–2.45, 𝑃 = 0.89).
4. Discussion
In the present study, we sought to investigate the effects
of ADT on cardiovascular outcomes in a cohort of Chi-
nese patients with nonmetastatic carcinoma of prostate
but without previously documented cardiovascular disease.
We showed that patients with nonmetastatic carcinoma of
prostate treated with ADT had higher incidences of cardio-
vascular events including newly diagnosed coronary artery
disease and congestive heart failure. Cox regression analysis
identified hypertension and ADT as the only independent
predictors of cardiovascular events in Chinese patients with
nonmetastatic carcinoma of prostate.
Carcinoma of prostate is the most common malignancy
in men with a lifetime risk of 1 in 6. In addition to
local therapies, such as surgery and radiotherapy, ADT is
an important systemic treatment because of the androgen
dependence of the disease [1]. However, concerns about
cardiovascular safety of ADT have been raised after the
publication of a large observational study using Medicare
database demonstrating the association between ADT and
diabetes mellitus, coronary artery disease, and sudden car-
diac death [5]. Subsequent observational studies likewise
have demonstrated that patients with carcinoma of prostate
receiving ADT had a higher incidence of coronary artery
disease [6], myocardial infarct [6], sudden cardiac death
[6, 9], and overall cardiovascular mortality [9, 10]. In a stark
contrast, data from randomized control trials comparing
ADT with placebo have failed to demonstrate any increase
risk in cardiovascular events associated with ADT [11, 12, 14–
22]. In a recentmeta-analysis summarizing eight randomized
control trials involving altogether 4,141 patients with high-
risk carcinoma of prostate randomized to receive ADT or
placebo, ADT has not been shown to be associated with any
significant risk of cardiovascular mortality [4]. One plausi-
ble explanation for such discrepancy between randomized
control trials and real-world observational registries may be
related to the differences in studied subjects in these two
settings. It has been postulated that as randomized control
trials tend to recruit mainly healthy subjects, thus vulner-
able patients with preexisting cardiovascular comorbidities
and/or diseases actually experiencing excess cardiovascular
events from ADTwere most likely underrepresented in these
4 Journal of Oncology
Table 2: Baseline characteristics of patients with and without primary composite endpoint.
No primary endpoint (𝑁 = 685) With primary endpoint (𝑁 = 60) 𝑃 value
Age, years 72.1 ± 0.3 73.4 ± 1.5 0.29
Hypertension, 𝑛 (%) 244 (35.6) 32 (53.5) <0.01∗
Hypercholesterolemia, 𝑛 (%) 75 (10.9) 4 (6.7) 0.39
Cigarette smoker, 𝑛 (%) 257 (37.5) 27 (45.0) 0.25
Lung disease, 𝑛 (%) 24 (3.5) 2 (3.3) 1.00
Carcinoma of prostate
PSA at diagnosis, ng/mL 348 ± 47 43 ± 13 0.07
Gleason score 0.20
2–5, 𝑛 (%) 34 (5.0) 6 (10.0)
6–8, 𝑛 (%) 444 (64.8) 37 (61.7)
9-10, 𝑛 (%) 133 (19.4) 8 (13.3)
Not specified, 𝑛 (%) 74 (10.8) 9 (15.0)
Treatment
Local treatment, 𝑛 (%) 452 (66.0) 34 (56.7) 0.15
ADT, 𝑛 (%) 466 (68.0) 51 (85.0) <0.01∗
Surgical ADT only, 𝑛 (%) 113 (16.5) 15 (25.0)
Medical ADT only, 𝑛 (%) 224 (32.7) 28 (46.7)
Medical and Surgical ADT, 𝑛 (%) 129 (18.8) 8 (13.3)
∗
𝑃 < 0.05 (comparison between patients with and without ADT.
ADT: androgen deprivation therapy; PSA: prostate specific antigen.
randomized trials [23]. By contrast, real-world registries
often include most if not all patients within a predefined
geographic location, thereby representing a more diverse
population of patients irrespective to their disease status and
preexisting cardiovascular diseases. Unfortunately, none of
the randomized control trials prestratified patients according
to their baseline cardiovascular comorbidities [11, 12, 14–
22]. Furthermore, information concerning preexisting car-
diovascular disease was not commonly provided in detail in
both published randomized control trials and observational
registries; thereby it remains difficult to ascertain such expla-
nation for the discrepancy.
In the present study, patients with carcinoma of prostate
receiving ADT had higher incidences of newly diag-
nosed coronary artery disease and congestive heart failure.
Although such findings were qualitatively consistent with
previously reported observational registries that patients with
carcinoma of prostate receiving ADT had significantly higher
risk of subsequent cardiovascular events comparedwith those
not on ADT [5, 6, 9, 10], there are nonetheless important
quantitative differences. For instance, the incidence of newly
diagnosed coronary artery disease among patients on ADT
ranged from 63.3 to 72.3 per 1,000 patient-years in the very
first publication raising the possible adverse cardiovascular
effects of ADT involving 73,196 patients with carcinoma of
prostate [5], which is 6-7 times higher than that of our cohort
(only 9.9% per 1,000 patient-years). Similarly, the incidence
of newly diagnosed coronary artery disease amongst patients
not receiving ADT in the same study was likewise much
higher than the present cohort (61.3 versus 2.6 per 1,000
patient-years) [5]. This may somehow reflect differences
in baseline cardiovascular risk between studies but may
also imply the baseline cardiovascular risk undermining
the vulnerability to subsequent cardiovascular events from
ADT. Indeed, in a retrospective cohort of 5,077 patients with
localized carcinoma of prostate that patients receiving ADT
had a higher all-cause mortality, such risk increased from
a HR of 1.3 amongst patients with no comorbidity to 1.4
amongst those with diabetes mellitus, hypertension, and/or
hypercholesterolemia and to 2.33 amongst those with preex-
isting congestive heart failure and/or myocardial infarction
[24]. In the present study, we excluded not only patients with
preexisting diabetes mellitus and/or coronary artery disease
as the previously captioned study [5] but also patients with
other preexisting conditions such as congestive heart failure,
ischemic stroke, chronic renal failure, and atrial fibrillation,
thereby representing patients with a very low cardiovascular
risk. Despite such low risk, the use of ADT was associated
with increased risk of cardiovascular events as in previously
reported cohorts at much higher risk. Counterintuitively, a
recent study by Vigen and colleagues involving 8,709 men
noted to have a total testosterone <300 ng/dL after coronary
angiography showed that individuals receiving testosterone
therapy had a higher incidence of composite events of
myocardial infarctions and strokes [25].While the underlying
mechanisms remain elusive, it has been postulated that the
nonphysiologic peak and trough levels of injectable form
of testosterone replacement may have contributed to the
development of cardiovascular diseases/events. It is possible
that, like other physiological phenomena, the association
between testosterone level and the development of cardiovas-
cular diseases/events exhibits a J-curve relationship. Taken
collectively, it appears that ADT confers a higher risk of
cardiovascular diseases to patients with carcinoma of prostate
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and themagnitude of such riskmaydependon the underlying
cardiovascular risk profile of individual patients. This in fact
concurs with the jointed recommendation from the Amer-
ican Heart Association, the American Cancer Society, and
the American Urological Association advocating periodic
cardiovascular risk surveillance for patients with carcinoma
of prostate on ADT [26].
Limitations. The study has several limitations. First, this
study is limited by the relative small sample size and being
a single-centered observational design. Second, given the
relatively low-risk population, the event rate was very low,
thus limiting the statistical power of the analyses of cause-
specific mortality. Third, due to lack of access to the details
of nature of ADT, the impact of the types as well as duration
of ADT on the development of cardiovascular diseases has
not been analyzed. Fourth, despite themultivariate regression
model demonstrating the association between ADT and
the primary composite endpoint (coronary artery disease,
congestive heart failure, and ischemic stroke), it is noteworthy
that patients on ADT were significantly older and possessed
higher prevalence of various cardiovascular risk factors than
those not on ADT. Finally, newer risk stratifiers such as
high sensitive C-reactive protein have not been assessed
routinely. This study nonetheless demonstrates that, even in
relatively low cardiovascular risk patients with nonmetastatic
carcinoma of prostate, ADT was associated with significant
higher cardiovascular event rate. Further studies are needed
to define the recommendations for risk stratification and
therapy in this group of patients.
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